Harbour BioMed, a clinical-stage biopharmaceutical company, has raised $102.8 million in Series C financing. The investors included Hudson Bay Capital, OrbiMed, Country Garden VC, GTJA Investment Group, Octagon Capital, Sage Partners and Greater Bay Area Investment Fund.
Source: Press Release
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: